StageOther Investors | Alive
Missing: CoRepair's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: CoRepair's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
CoRepair Frequently Asked Questions (FAQ)
What is CoRepair's latest funding round?
CoRepair's latest funding round is Other Investors.
Who are the investors of CoRepair?
Investors of CoRepair include Charter Life Sciences.
Who are CoRepair's competitors?
Competitors of CoRepair include NeoChord, Ancora Heart, Innara Health, SynCardia Systems, Corassist Cardiovascular, Respicardia, Celonova Biosciences, TherOx, NxStage Medical, Sonivate Medical and 43 more.
Compare CoRepair to Competitors
Cardiola have designed a patented device, the m.pulse device designed to treat chronic heart failure (CHF), non-surgically, in a patient's home.
NeoChord is a medical technology company engaged in the advancement of beating heart mitral valve repair in patients suffering from mitral valve regurgitation. The company's flagship product, the NeoChord Artificial Chordae Delivery System, is a beating heart procedure, echo-guided treatment for patients with mitral valve regurgitation and is proven to resolve and restore normal mitral valve function. The company was founded in 2007 and is based in Minneapolis, Minnesota.
Cardiac Power is a non-blood-contacting left ventricular assist device for the treatment of congestive heart failure
Viacor is a development stage company dedicated to pioneering catheter-based techniques for the treatment of congestive heart failure.
CardioKinetix develops a percutaneous treatment for patients with left ventricular dilation after an anterior myocardial infarction (MI). The implantable device, called the PARACHUTE is a partitioning membrane deployed within the compromised ventricle. The PARACHUTE partitions the damaged muscle, isolating the non-functional muscle segment from the functional segment, and decreases the overall volume. Options for patients whose ventricle has enlarged are limited, with most on medical therapy and/or a cardiac resynchronization device that only benefits heart failure patients with a specific EKG pattern.
Chase Medical is developing medical technology for treating congestive heart failure. Chase Medical is developing a device called the Mannequin which aims to help the heart maintain its shape while going through reconstruction of the left ventricle.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.